AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics
AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics.
Recent News
Recent Posts
- AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors April 2022
- AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild April 2022
- AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC) April 2022
- Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session March 2022